EP 2310021 A4 20120627 - METHODS OF USING COMPOSITIONS COMPRISING MIR-192 AND/OR MIR-215 FOR THE TREATMENT OF CANCER
Title (en)
METHODS OF USING COMPOSITIONS COMPRISING MIR-192 AND/OR MIR-215 FOR THE TREATMENT OF CANCER
Title (de)
VERFAHREN ZUR VERWENDUNG VON ZUSAMMENSETZUNGEN MIT MIR-192 UND/ODER MIR-215 ZUR BEHANDLUNG VON KREBS
Title (fr)
PROCÉDÉS D'UTILISATION DE COMPOSITIONS COMPORTANT MIR-192 ET/OU MIR-215 POUR LE TRAITEMENT D'UN CANCER
Publication
Application
Priority
- US 2009050028 W 20090709
- US 7977108 P 20080710
Abstract (en)
[origin: WO2010006111A2] The invention provides methods and compositions for inhibiting the proliferation of mammalian cells. In some embodiments, the methods comprise contacting mammalian cells with an effective amount of at least one small interfering nucleic acid (siNA) agent that inhibits the level of expression of at least two miR 192 family responsive genes selected from the group consisting of SEPT 10, LMNB2, HRH1, HOXA10, ERCC3, MIS12, MPHOSPHI1, CDC7, SMARCB1, MAD2L1, DTL, RACGAP1, MCM10, PIM1, DLG5, BCL2, CUL5, and PRPF38A.
IPC 8 full level
A61K 31/70 (2006.01); C12N 15/00 (2006.01); C12N 15/113 (2010.01)
CPC (source: EP US)
A61P 35/00 (2017.12 - EP); C12N 15/113 (2013.01 - EP US); C12N 2310/14 (2013.01 - EP US); C12N 2310/141 (2013.01 - EP US); C12N 2330/10 (2013.01 - EP US)
Citation (search report)
- [I] WO 2004045543 A2 20040603 - DHARMACON INC [US]
- [I] WO 2007147067 A2 20071221 - ROSETTA INPHARMATICS LLC [US], et al
- [I] WO 2008036776 A2 20080327 - ASURAGEN INC [US], et al
- [I] EP 1640452 A1 20060329 - NIPPON SHINYAKU CO LTD [JP]
- [I] WO 03070969 A2 20030828 - SIRNA THERAPEUTICS INC [US], et al
- [E] EP 2213738 A2 20100804 - DHARMACON INC [US] & DATABASE EMBL [online] 18 August 2010 (2010-08-18), "Sequence 308680 from Patent EP2213738.", XP002675480, retrieved from EBI accession no. EMBL:HD431964 Database accession no. HD431964
- [I] FUTAMI T ET AL: "Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, no. 2, 1 January 2002 (2002-01-01), pages 251 - 252, XP002968175, ISSN: 0305-1048
- [L] E. ELVIRA-MATELOT ET AL: "Regulation of WNK1 Expression by miR-192 and Aldosterone", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 21, no. 10, 2 September 2010 (2010-09-02), pages 1724 - 1731, XP055026444, ISSN: 1046-6673, DOI: 10.1681/ASN.2009111186
- [L] SÃ Â NIA MONIZ ET AL: "Emerging roles for WNK kinases in cancer", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHÄUSER-VERLAG, BA, vol. 67, no. 8, 22 January 2010 (2010-01-22), pages 1265 - 1276, XP019797959, ISSN: 1420-9071
- [IP] BO SONG ET AL: "miR-192 Regulates Dihydrofolate Reductase and Cellular Proliferation through the p53-microRNA circuit", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 14, no. 24, 15 December 2008 (2008-12-15), pages 8080 - 8086, XP008138919, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-08-1422
- [IP] CHRISTIAN J BRAUN ET AL: "p53-Responsive MicroRNAs 192 and 215 Are Capable of Inducing Cell Cycle Arrest", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 68, no. 24, 15 December 2008 (2008-12-15), pages 10094 - 10104, XP008138920, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-08-1569
- [IP] SARA A. GEORGES ET AL: "Cell cycle arrest or apoptosis by p53: Are microRNAs-192/215 and -34 making the decision?", CELL CYCLE, vol. 8, no. 5, 1 March 2009 (2009-03-01), pages 677 - 682, XP055026247, ISSN: 1538-4101, DOI: 10.4161/cc.8.5.8076
- See references of WO 2010006111A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
DOCDB simple family (publication)
WO 2010006111 A2 20100114; WO 2010006111 A3 20100304; EP 2310021 A2 20110420; EP 2310021 A4 20120627; US 2011118337 A1 20110519
DOCDB simple family (application)
US 2009050028 W 20090709; EP 09795161 A 20090709; US 200913003536 A 20090709